$ASMB News

Assembly Biosciences to Present Positive Phase 1a Safety, Tolerability and Target Engagement Data for ABI-6250 at AASLD The Liver Meeting® 2026

Assembly Biosciences To Present New Phase 1a Data From Its ABI-6250 Program At The Liver Meeting 2026

Assembly Biosciences to Present at the H.C. Wainwright & Co. 28th Annual Global Investment Conference

Wall Street Analysts See a 35.71% Upside in Assembly Biosciences (ASMB): Can the Stock Really Move This High?

Should You Buy Assembly Biosciences (ASMB) After Golden Cross?

Here's Why Momentum in Assembly Biosciences (ASMB) Should Keep going

Mizuho Maintains Outperform on Assembly Biosciences, Lowers Price Target to $45

Are You Looking for a Top Momentum Pick? Why Assembly Biosciences (ASMB) is a Great Choice

Wall Street Analysts Think Assembly Biosciences (ASMB) Could Surge 40.66%: Read This Before Placing a Bet

HC Wainwright & Co. Reiterates Buy on Assembly Biosciences, Maintains $50 Price Target

Assembly Biosciences (ASMB) Reports Q2 Loss, Beats Revenue Estimates

Assembly Biosciences Q2 EPS $(0.20) Beats $(0.65) Estimate, Sales $13.374M Beat $8.599M Estimate

Assembly Biosciences: A Gilead-Backed Antiviral Option With More Embedded Leverage Than The Market Appreciates

Mizuho Maintains Outperform on Assembly Biosciences, Raises Price Target to $45

Assembly Biosciences, Inc. (ASMB) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

Assembly Biosciences Announces Upcoming Investor Conference Presentations

Guggenheim Reiterates Buy on Assembly Biosciences, Maintains $43 Price Target

Assembly Biosciences Announces the Closing of its Offering of Common Stock and Pre-Funded Warrants and Full Exercise of the Underwriters’ Option to Purchase Additional Shares

Assembly Biosciences Announces Pricing of $100 Million Offering of Common Stock and Pre-Funded Warrants

Assembly Biosciences Announces Expansion of ABI-6250 Clinical Development Into Cholestatic Liver Diseases